Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Affiliations

Comment

Pennan M Barry et al. Am J Respir Crit Care Med. 2017.

. 2017 Dec 1;196(11):1488-1489.

doi: 10.1164/rccm.201701-0013LE.

No abstract available

Comment in

Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
van Leth F, Günther G, Hoffmann H, Lange C; European MDR-TB Database Collaboration. van Leth F, et al. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1489-1490. doi: 10.1164/rccm.201705-0995LE. Am J Respir Crit Care Med. 2017. PMID: 28715229 No abstract available.
Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
Varaine F, Guglielmetti L, Mitnick CD. Varaine F, et al. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1490-1491. doi: 10.1164/rccm.201705-0988LE. Am J Respir Crit Care Med. 2017. PMID: 28715258 No abstract available.

Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe.
Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, Oliveira O, Rumetshofer R, Veziris N, van Leth F; European MDR-TB database collaboration *. Lange C, et al. Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE. Am J Respir Crit Care Med. 2016. PMID: 27685538 No abstract available.
Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD. Varaine F, et al. Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. doi: 10.1164/rccm.201605-1080LE. Am J Respir Crit Care Med. 2016. PMID: 27739887 No abstract available.